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OBJECTIVES This study assessed the algesic activity of bradykinin (BK) in humans and the effects of
acetylsalicylate on muscular and cardiac BK-induced pain.
BACKGROUND Bradykinin is released by the ischemic myocardium and may be involved in the genesis of
ischemic pain.
METHODS Increasing doses of BK (from 30 to 960 ng/min) were randomly infused, for periods of 2 min
each, into the iliac artery of 10 patients. The same protocol was repeated 30 min after the IV
administration of 1 g of acetylsalicylate. In eight other patients with coronary artery disease,
the same increasing doses of BK, for periods of 2 min each, were infused into the left coronary
artery. The same protocol was repeated 30 min after the IV administration of 1 g of
acetylsalicylate. Time to pain onset and maximal pain severity were obtained.
RESULTS Before acetylsalicylate administration, all patients experienced pain during intra-iliac infusion
of BK. After acetylsalicylate, eight patients did not experience any pain during BK infusion
(p 5 0.0014), and in the two remaining patients, time to pain onset and maximal pain severity
were similar to those recorded before acetylsalicylate. Before acetylsalicylate administration,
all patients experienced pain similar to their habitual angina during intracoronary BK
infusion. After acetylsalicylate, six patients did not experience any pain during BK infusion
(p 5 0.0098), whereas in the two remaining patients time to pain onset and maximal pain
severity were similar to those recorded before acetylsalicylate.
CONCLUSIONS Intra-iliac infusion of BK causes muscular pain, and its intracoronary infusion in patients with
coronary artery disease causes cardiac pain, which is similar to their habitual angina. The
BK-induced pain is abolished or reduced by acetylsalicylate, thus suggesting that
acetylsalicylate-sensitive mediators, such as prostaglandins, are involved in its pathogenesis.
(J Am Coll Cardiol 1999;34:216–22) © 1999 by the American College of Cardiology
Bradykinin (BK), a polypeptide with potent vasodilator and
algesic properties, is released in large amounts by ischemic
myocardium (1) and is believed to be a mediator of cardiac
ischemic pain (2–5). Applied directly to the exposed epi-
cardium, BK stimulates afferent nerve endings (6), and
autoradiographic studies have demonstrated BK receptors in
myocardial-sensory neurons (7). Furthermore, a number of
experimental studies have shown the antinociceptive effects
of BK antagonists (7–9). Although BK has been used for
more than 20 years as a pain-causing substance, and
although there is convincing experimental evidence that BK
causes activation of cardiac afferent nerves, its precise role in
the genesis of cardiac pain in humans remains uncertain.
To establish the role played by BK in the genesis of
cardiac pain and to explore the mechanisms of its algesic
properties, we carried out a systematic study in humans of
intra-arterial BK infusion before and after administration of
acetylsalicylate.
METHODS
The study protocols were approved by the institutional
Ethics Committee, and all patients gave informed signed
consent.
Bradykinin and adenosine preparation. The BK (50 mg
in ampules of 1 ml of physiologic saline solvent) was
provided by Clinalfa AG (Laufelfingen, Switzerland).
Adenosine (2.7 mg/ml in ampules of 2 ml) was provided by
Sigma Tau Pharmaceutics (Pomezia, Italy). Both substances
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were stored at 260°C and were dissolved in normal saline to
the final concentrations on the day of the study.
Intra-iliac study. A total of 10 consecutive patients with
coronary artery disease (8 men; mean age 61 6 9 years;
range 48 to 71 years) who did not show any evidence of
peripheral vascular disease (ankle-brachial index .1 as-
sessed by vascular Doppler) participated in this study.
Calcium channel-blocking and beta-adrenergic blocking
agents were withdrawn two days before the study. Patients
were also requested to abstain from xanthine-containing
drugs, food, and drinks for at least 48 h before the study. At
the end of routine cardiac catheterization, patients under-
went a randomized cross-over study of the algogenic effects
of the infusion of BK and adenosine (Fig. 1). After
heparinization (5,000 IU IV), a 5F catheter was inserted
through a 7F femoral sheath and advanced into the right
external iliac artery. Either BK (at increasing doubling doses
from 30 to 960 ng/min for periods of 2 min each) or
adenosine (at increasing doubling doses from 108 to
3,456 mg/min for periods of 2 min each) was then infused.
Either BK or adenosine infusion was continued also after
pain onset to complete the infusion protocol. The time to
pain onset (in seconds from the beginning of the infusion)
and maximal pain severity were recorded. Six patients
received BK, and four patients received adenosine as first
infusion. Arterial blood pressure, obtained via the side port
of the femoral sheath, and the standard 12 electrocardio-
graphic (ECG) leads were recorded continuously through-
out the study. The same infusion protocols were repeated,
after a second randomization, 30 min after IV infusion of
1 g of lysine acetylsalicylate (Sanofi Winthrop, Milan, Italy).
Five patients received BK and five patients received aden-
osine as first infusion.
ASSESSMENT OF BLOOD FLOW VELOCITY. Right iliac artery
blood flow velocity was measured at baseline and after every
step of infusion of BK or adenosine by using an intravascular
0.014-in. Doppler guide wire (FloWire and FloMap, Car-
diometrics, Inc.). A Doppler guide wire was advanced
through the 5F femoral sheath into the right external iliac
artery and positioned until an optimal and stable Doppler
signal, not in the proximity of a side branch, was obtained.
Blood flow velocity was calculated from the Doppler fre-
quency shift of a reflected 15-MHz signal by fast Fourier
transformation and displayed in a spectral format, as previ-
ously described (10). Flow velocity signals were continu-
ously displayed throughout the study. Average peak velocity
(cm/s) was derived automatically by the integrated signal-
analyzing computer. Satisfactory velocity data were obtained
for all 10 patients. A derived resistance-related index (mean
blood pressure/average blood flow velocity) was calculated at
the end of each infusion dose.
Intracoronary study. Eight patients (6 men; mean age
59 6 11 years, range 44 to 65 years) with stable angina
pectoris and significant left coronary artery atherosclerosis
participated in this study. No patient had suffered a previous
myocardial infarction. All patients had an exercise test
positive for myocardial ischemia and angina. All patients
had at least one significant coronary artery stenosis (internal
diameter reduction .70% by visual assessment): 3 patients
had significant stenosis in the left anterior descending
coronary, 2 patients in the proximal circumflex, and 3
patients in both arteries. All patients were normotensive, in
sinus rhythm and without evidence of heart failure, cardio-
myopathy or valvular disease. Patients with history of
glucose intolerance were excluded from the study. No
patient had evidence of left ventricular hypertrophy or
conduction defects that could interfere with the interpreta-
tion of ST-segment changes, and no patient was taking
digitalis. Calcium channel-blocking and beta-blocking
agents were withdrawn two days before the study. Patients
were also requested to abstain from xanthine-containing
drugs, food and drinks for at least 48 h before the study.
On completion of the diagnostic angiograms of both
coronary arteries and after further heparinization (5,000 IU
IV), the left coronary artery was recannulated with a 5F
catheter. Increasing doubling doses of BK (from 30 to
Figure 1. Diagrammatic representation of the infusion protocol for intra-iliac study. After randomization, BK or adenosine was infused
at increasing doses for periods of 2 min each. At the onset of pain, either BK or adenosine infusion was continued to complete the infusion
protocol and was then stopped. Ten minutes after the disappearance of BK or adenosine-induced pain, the cross-over infusion with
adenosine or BK was carried out. At the end of the first phase of the infusion protocol, acetylsalicylate was infused intravenously. Thirty
minutes after the end of acetylsalicylate infusion a second randomization was performed, and the same infusion protocol with BK or
adenosine was repeated.
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960 ng/min for periods of 2 min each) were then infused
into the left coronary artery. At the onset of pain the
infusion of BK was continued to complete all the infusion
protocol and was then stopped. Both the time to the onset
of pain (in seconds from the beginning of the infusion) and
maximal pain severity were recorded. The same infusion
protocol was repeated 30 min after the IV infusion of 1 g of
lysine acetylsalicylate. Arterial blood pressure, obtained via
the side port of the 7F femoral sheath, and the standard 12
ECG leads were continuously recorded throughout the
study.
Assessment of pain. At the beginning of each BK or
adenosine infusion, patients were informed that they might
develop pain because of the procedure; this request was not
repeated during the infusion of BK or adenosine to avoid
any potential bias. Patients were also instructed to report
promptly the onset of pain and to record the maximal
severity of the pain. Immediately after the infusions, pa-
tients were asked to report the maximal severity of pain
using a visual analog scale (11). To this end the 100-mm
scale was marked from no symptoms to severe symptoms.
The scale was measured from 0 to the subject’s mark in
millimeters (mm). All subjects were blinded to the nature of
the infused materials. Testing personnel were aware of the
nature of the infused materials.
Statistical analysis. Continuous normally distributed data
are expressed as mean 61 SD and were analyzed by
two-tailed paired Student t test. Data on pain severity,
which are not normally distributed, are expressed as median
and interquartile range and analyzed using the Wilcoxon
rank-sum test. Repeated measures analysis of variance
(ANOVA) was used to compare the effects of BK and
adenosine over time regarding heart rate, mean systemic
blood pressure and resistance index; for a p value ,0.05,
parities comparisons were performed by using the Scheffe´ F
test. Proportions were compared by using the chi-square
test. Differences were considered to be statistically signifi-
cant at a p value ,0.05.
RESULTS
Intra-Iliac Study
Infusion of BK and adenosine before acetylsalicylate
administration. All patients experienced pain localized to the
right leg during infusion of both BK and adenosine. During
the BK infusion, seven patients described the pain as a feeling
of heaviness associated with burning involving the entire limb
below the site of injection, and three patients as severe cramp.
Of note, three patients lamented to feeling a sensation of
burning at the sole of the right foot and in the fingertips.
During the infusion of adenosine, eight patients described the
pain as a feeling of heaviness localized at the right leg with
some burning sensations, and two patients as a severe cramp.
In all patients, pain severity and time to the onset of pain were
similar during the infusion of BK and adenosine (50 mm,
interquartile range 30 to 65 vs. 54 mm, interquartile range 50
to 75, p 5 0.135 and 477 6 156 vs. 449 6 139 s, p 5 0.288)
(Fig. 2). The pain disappeared spontaneously within 60 s of the
end of the infusions in all patients.
No patient exhibited ECG changes during infusion of BK
or of adenosine. Compared with baseline values, heart rate
showed a mild but significant increase at the highest dose of
BK and adenosine (68 6 8 vs. 64 6 9 beats/min, p 5 0.048
and 69 6 9 vs. 63 6 8 beats/min, p 5 0.043); mean arterial
blood pressure was similar (100 6 15 vs. 105 6 12 mm Hg,
p 5 NS and 101 6 10 vs. 104 6 8 mm Hg, p 5 NS). The
resistance index decreased similarly during the infusion of both
BK (p , 0.001 baseline vs. peak) and adenosine (p , 0.001
baseline vs. peak) (Fig. 3A).
Infusion of BK and adenosine after acetylsalicylate ad-
ministration. After the administration of acetylsalicylate,
eight patients did not experience any pain, even during the
infusion of the highest dose of BK (p 5 0.0014 vs.
prevalence of pain before acetylsalicylate administration). In
the two remaining patients, pain severity and the time to
pain onset were similar to that recorded before acetylsalic-
ylate administration (Fig. 2). Conversely, the infusion of
adenosine caused pain in all patients, and pain severity and
the time to pain onset did not change compared with those
recorded before acetylsalicylate administration (60 mm,
interquartile range 54 to 70 mm vs. 54 mm, interquartile
range 50 to 75 mm, p 5 NS and 402 6 160 vs. 449 6 139 s,
p 5 NS). Eight patients described the pain as a feeling of
heaviness localized at the right leg, and two patients
described a severe cramp. The character of the pain during
the infusion of adenosine was similar to that reported before
acetylsalicylate administration. The pain disappeared spon-
taneously within 60 s of the end of the infusions in all
patients. Compared with baseline values, heart rate showed
a mild but significant increase at the highest dose of BK and
adenosine (69 6 9 vs. 61 6 9 beats/min, p 5 0.035 and
70 6 9 vs. 60 6 8 beats/min, p 5 0.031); mean arterial
blood pressure was similar (102 6 13 vs. 107 6 11 mm Hg,
p 5 NS and 102 6 10 vs. 107 6 9 mm Hg, p 5 NS). The
resistance index decreased similarly during the infusion of
both BK (p , 0.001 peak vs. baseline) and adenosine (p ,
0.001 peak vs. baseline) (Fig. 3B).
Intracoronary Study
Infusion of BK before acetylsalicylate administration.
All patients experienced chest pain during BK infusion.
Median pain severity was 55 mm, interquartile range 32 to
70 mm and mean time to pain onset 536 6 167 s (Fig. 4).
In seven patients the severity, localization, and radiation of
BK-induced pain were similar to those experienced during
daily life. In particular, in six patients both BK-induced pain
and spontaneous pain were localized in the retrosternal
region without any radiation. In one patient, both BK-
induced pain and spontaneous pain were localized in the
retrosternal region with radiation to the left shoulder. In the
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remaining patient, BK infusion caused retrosternal pain
with radiation to the neck, both arms, and the epigastric
region, whereas spontaneous pain was limited to the chest.
The pain disappeared spontaneously within 60 s of the end
of the infusions in all patients. No patient exhibited ECG
changes during the BK infusion. Compared with baseline
values, heart rate showed a mild but significant increase at
the highest dose of BK (68 6 11 vs. 63 6 7 beats/min, p 5
0.02); mean arterial blood pressure was similar (109 6 10 vs.
112 6 10 mm Hg, p 5 NS).
Infusion of BK after acetylsalicylate administration. Af-
ter the administration of lysine acetylsalicylate, six patients
did not experience any pain at all, even during the infusion
of the highest dose of BK (p 5 0.0098 vs. prevalence of pain
before lysine acetylsalicylate administration). In the two
remaining patients maximal pain severity and time to pain
onset were similar to those experienced before acetylsalicy-
late administration (Fig. 4). The pain disappeared sponta-
neously within 60 s of the end of the infusions. Compared
with baseline values, heart rate showed a mild but significant
increase at the highest dose of BK (66 6 10 vs. 62 6 8
beats/min, p 5 0.04); mean arterial blood pressure was
similar (112 6 10 vs. 112 6 11 mm Hg, p 5 NS).
DISCUSSION
Bradykinin has been generally regarded as one of the most
likely chemical mediators of ischemic pain (2–5,12). Indeed,
BK is formed and released from the ischemic tissue within
minutes of the onset of hypoxia or ischemia (13,14), and its
algesic properties have been demonstrated in a variety of
animal models (15). Furthermore, BK receptors have been
localized over myocardial and coronary visceral nociceptive
afferents, and several BK antagonists have been shown to
block BK-induced acute vascular pain in animal models
(7,8). However, despite this strong experimental evidence,
in other studies the algogenic effects of BK have been
disputed (16–18).
Results of the present study consistently show that, in
humans, the intra-iliac infusion of BK causes pain similar to
that provoked by adenosine, a known mediator of ischemic
pain in man (19–21); furthermore, intracoronary infusion of
BK in patients with symptomatic coronary artery disease
caused cardiac pain that was similar to their habitual angina.
Finally, in most individuals, acetylsalicylate abolished or
reduced both muscular and cardiac pain induced by intra-
arterial and intracoronary BK infusion and yet, it did not
affect BK-induced vasodilation. These results indicate that
BK is a potential mediator of ischemic pain in man and that
its algesic effects are mainly mediated by acetylsalicylate-
sensitive mediators.
Previous studies in humans. Bradykinin has been shown
to cause pain by intradermal injection (22), on a blister base
preparation (2,23,24) and intra-arterially (3,25,26). In 1963,
Burch and Depasquale reported that injection of 1 to 10 mg
of synthetic BK into the brachial artery produced pain in all
the subjects studied (3). Interestingly, there was no tachy-
Figure 2. Maximal pain severity (median values and interquartile ranges) and time to pain onset (mean values 6 SD) during the intra-iliac
infusion of BK (squares) and adenosine (circles), before and after acetylsalicylate administration. The maximal duration of the infusion
was 750 s.
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phylaxis of the pain to repeated intra-arterial injections. The
absence of tachyphylaxis was later confirmed by Coffman
(26), who showed that the latency of pain response and pain
severity remained essentially unchanged with BK injections
given at 15-min intervals for 2 h. Furthermore, in this latter
study, pain induced by the intra-arterial injection of BK was
not related to its vasodilatory effect and was reduced or
abolished after the oral administration of buffered sodium or
calcium acetylsalicylic acid. More recently, the intracoronary
administration of BK in individuals with and without
coronary artery disease was shown to elicit a painful sensa-
tion, which, however, in patients with ischemic heart
disease appeared to be different from their habitual angina
(17). Finally, in contrast to effects observed in dogs (1),
Eldar et al. (18) reported that ischemic pain induced by the
occlusion of left anterior descending coronary artery during
balloon angioplasty was not associated with an increase in
BK plasma levels in the great cardiac vein.
The present study. In our study, the intra-arterial infusion
of BK caused a painful sensation, which, in most individu-
als, was similar to that elicited by the infusion of adenosine,
the only mediator of ischemic pain so far identified in
humans (19–21,27). Furthermore, the intracoronary infu-
sion of BK caused chest pain, which was described by all
patients but one as indistinguishable from their habitual
angina during everyday life. In a recent study, Schaefer et al.
(17) reported that the intracoronary injection of BK in
patients with coronary atherosclerosis caused chest pain that
appeared to be different from angina. The different findings
of the study conducted by Schaefer et al. (17) and ours are
probably due to the substantially different study protocols.
Indeed, in the Schaefer study repeated intracoronary bolus
injections instead of graded infusion of BK were used; thus,
the effective doses of BK administered in the two studies are
not directly comparable. As a proof of that, in the study by
Schaefer et al. (17), marked changes in blood pressure and
heart rate were observed that were often associated with
flushing and nausea. By contrast, in our study, no major
changes in blood pressure and heart rate or systemic side
effects were observed.
The possibility that the pain induced by BK might be
related to its marked vasodilating effect is made unlikely by
the observation that other potent vasodilators such as
Figure 3. Effect of increasing doses of BK or adenosine on the
resistance index before (Panel A) and after acetylsalicylate admin-
istration (Panel B). Data are mean 6 SD. Differences between
groups (BK and adenosine) before and after acetylsalicylate ad-
ministration at the different steps were not significant. *p , 0.001
compared with baseline values.
Figure 4. Maximal pain severity (median values and interquartile
ranges) and time to pain onset (mean values 6 SD) during
intracoronary infusion of BK, before and after acetylsalicylate
administration. The maximal duration of the infusion was 750 s.
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nifedipine and nitrates do not cause pain when infused
intra-arterially or intracoronary (19); furthermore, pain
elicited by BK in our study constantly appeared later than
BK-induced maximal vasodilation. Finally, in the present
study, IV administration of acetylsalicylate in a dose capable
to markedly inhibit cyclo-oxygenase (28) abolished or sig-
nificantly reduced BK-induced pain in most subjects, but it
did not affect BK-induced vasodilation.
The ability of acetylsalicylate to prevent BK-induced pain
but not adenosine-induced pain suggests that BK but not
adenosine acts through the release of arachidonic acid
metabolites. Of note, acetylsalicylate administration could
not prevent pain induced by infusion of BK in all patients
both when infused intra-arterially and intracoronary, thus
suggesting that, in some subjects, BK can also act through
mechanisms insensitive to acetylsalicylate.
The reason why in this study acetylsalicylate abolished or
reduced BK-induced pain although it does not seem to
abolish pain in patients during myocardial ischemia may
have different explanations. First, ischemic pain might be
caused by different chemical mediators acting on different
receptors through different mechanisms. Accordingly, in
previous studies (20,21,29), we have shown that pretreat-
ment with theophylline and bamiphylline, both antagonists
of adenosine, reduced but did not abolish exercise-induced
angina, thus suggesting that multiple mediators are involved
in the pathogenesis of cardiac ischemic pain.
Second, in our study, we used a rather high IV dose of
acetylsalicylate, substantially higher than the usual dose of
aspirin given to patients. A randomized, placebo-controlled
trial of the effects of acetylsalicylate on exercise-induced
angina is warranted to establish whether prostaglandins play
a role in the generation of cardiac ischemic pain.
In our study, acetylsalicylate did not prevent the marked
vasodilation induced by BK, thus suggesting that the vaso-
dilating action of BK, which is comparable to that of
adenosine, is independent from arachidonic acid metabo-
lites. This finding is consistent with the results of Pelc et al.
(30), who recently showed that pretreatment with indo-
methacin, a potent cyclo-oxygenase blocker, does not affect
BK-mediated increases in total left ventricular blood flow.
Study limitations. A critical issue in our study was the
assessment of pain. To this end we used the visual analog
scale, which has been extensively validated by Huskisson
(11). Its reproducibility is confirmed by observations in
previous studies that pain severity during infusion of aden-
osine before and after placebo is similar. Furthermore,
testing personnel were not unaware of the nature of the
infused materials, and patients themselves, who were un-
aware of the nature of the infused materials, marked the
visual analog scale. A limitation of our study is that we
cannot rule out that the attenuation of BK-induced pain
after acetylsalicylate was merely due to tachyphylaxis. How-
ever, this possibility appears to be remote; indeed, previous
studies failed to show tachyphylaxis for pain provoked by
repeated intra-arterial injections of BK (3,26). Lack of
tachyphylaxis is further supported by the observation in our
study that BK-induced vasodilation was similar during the
first and second infusion.
Finally, our findings suggest but do not prove that BK is
a mediator of angina. The definitive answer would require
the demonstration that a BK receptor antagonist prevents
spontaneously occurring angina pectoris as previously done
for other putative pain mediators such as adenosine (19,29).
Conclusions. This study shows that the intra-iliac infusion
of BK causes muscular pain similar to that elicited by the
infusion of adenosine, a known mediator of ischemic pain in
humans, and that its intracoronary infusion in patients with
angina and coronary artery disease causes cardiac pain
similar to their habitual angina. Moreover, BK-induced
pain is abolished or reduced by acetylsalicylate, thus sug-
gesting that acetylsalicylate-sensitive mediators, such as
prostaglandins, are involved in the pathogenesis of BK-
induced pain. As BK is released in large amounts by the
heart during ischemia, it can be a natural stimulus for
causing, via arachidonic acid metabolites, excitation of the
sensory receptors signaling the pain during myocardial
ischemia.
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